A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Top Cited Papers

6 December 2001

journal article
research article
Published by Massachusetts Medical Society in New England Journal of Medicine

Vol. 345 (23) , 1667-1675
https://doi.org/10.1056/nejmoa010713

Abstract

Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.

Keywords

This publication has 26 references indexed in Scilit:

Up-Regulation of AT1 and AT2 Receptors in Postinfarcted Hypertrophied Myocytes and Stretch-Mediated Apoptotic Cell Death
The American Journal of Pathology, 2000
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
New England Journal of Medicine, 1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet, 1999
Effects of angiotensin-II infusion at pressor and subpressor doses on endothelbv-1 plasma levels in healthy men
Life Sciences, 1997
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
New England Journal of Medicine, 1996
Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression.
Journal of Clinical Investigation, 1994
Tissue renin-angiotensin system in myocardial hypertrophy and failure
Archives of internal medicine (1960), 1993
CIRCULATING ANGIOTENSIN II LEVELS UNDER REPEATED ADMINISTRATION OF LISINOPRIL IN NORMAL SUBJECTS
Clinical and Experimental Pharmacology and Physiology, 1992
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
New England Journal of Medicine, 1987
Vasodilator Therapy for Heart Failure
Circulation, 1973